Recursion Pharmaceuticals (MEX:RXRX) DeferredTaxAndRevenue: MXN591 Mil (As of Mar. 2026)


MEX:RXRX Recursion Pharmaceuticals Inc MEX:RXRX
57 GF Score
Price MXN62.20
GF Value MXN73.63
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals DeferredTaxAndRevenue?

Recursion Pharmaceuticals MEX:RXRX -10.37% 57 DeferredTaxAndRevenue is MXN591 Mil as of Mar. 2026. GuruFocus rates MEX:RXRX with a GF Score™ of 57/100 and a GF Value™ of MXN73.63 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Recursion Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was MXN591 Mil.

Recursion Pharmaceuticals DeferredTaxAndRevenue Related Terms

Recursion Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals DeferredTaxAndRevenue Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 205.14 1,105.93 618.30 1,288.19 677.10

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 811.19 747.33 868.86 677.10 591.36
MEX:RXRX
57GF Score
Recursion Pharmaceuticals Inc MEX:RXRX
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of MXN591 Mil mean?
Recursion Pharmaceuticals (MEX:RXRX) has a DeferredTaxAndRevenue of MXN591 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Recursion Pharmaceuticals.
Is Recursion Pharmaceuticals' DeferredTaxAndRevenue too high?
Recursion Pharmaceuticals' current DeferredTaxAndRevenue is MXN591 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' DeferredTaxAndRevenue compare to ABSI and GLUE?
Recursion Pharmaceuticals' DeferredTaxAndRevenue of MXN591 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Recursion Pharmaceuticals. Recursion Pharmaceuticals's current DeferredTaxAndRevenue is MXN591 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current DeferredTaxAndRevenue is MXN591 Mil. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current DeferredTaxAndRevenue is MXN591 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:RXRX:

  • DeferredTaxAndRevenue: MXN591 Mil
  • GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:USA
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score

Get the complete analysis for MEX:RXRX

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.20
Price
MXN73.63
GF Value